Evidence map›Paper›PMID 40799389›Full record

ArticleiScience2025

MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD.

Alexander R Oles, Peter Y Yu, Abasi-Ama Udeme, Sudarshana Sharma, Priya Londhe, Benjamin R Pryce, Erin E Talbert, Eric M Hill, Carlos J Miranda, Brian K Kaspar and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alexander R OlesDepartment of Pediatrics, Darby Children's Research Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Peter Y YuDepartment of Cancer Biology and Genetics, The Ohio State University Medical Center, Columbus, OH 43210, USA.
Abasi-Ama UdemeDepartment of Pediatrics, Darby Children's Research Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Sudarshana SharmaHollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
Priya LondheDepartment of Cancer Biology and Genetics, The Ohio State University Medical Center, Columbus, OH 43210, USA.
Benjamin R PryceDepartment of Pediatrics, Darby Children's Research Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Erin E TalbertDepartment of Health and Human Physiology, and the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.
Eric M HillDepartment of Cancer Biology and Genetics, The Ohio State University Medical Center, Columbus, OH 43210, USA.
Carlos J MirandaDepartment of Pediatrics, Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH 43205, USA.
Brian K KasparDepartment of Pediatrics, Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH 43205, USA.
Michael A ArnoldDepartment of Pathology and Laboratory Medicine, Children's Hospital Colorado, Aurora, CO 80045, USA.
Jack HylandDepartment of Pediatrics, Darby Children's Research Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Cheryl A LondonCummings School of Veterinary Medicine, Tufts University, Medford, MA 02155, USA.
Peter J HoughtonGreehey Children's Cancer Research Institute, University of Texas, San Antonio, TX 23220, USA.
David J WangDepartment of Pediatrics, Darby Children's Research Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Ryan D RobertsDepartment of Pediatrics, Center for Childhood Cancer, Nationwide Children's Hospital, Columbus, OH 43205, USA.
Denis C GuttridgeDepartment of Pediatrics, Darby Children's Research Institute, Medical University of South Carolina, Charleston, SC 29425, USA.

Funding

Elucidating and exploiting the mechanisms by which IL-6 and IL-8 facilitate osteosarcoma metastasisK08CA201638 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI ROBERTS, RYAN D. · 2016 to 2020
$815k
NCI NIH HHS K08 CA201638
6 · The paper itself

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue cancer among children, characterized by a skeletal muscle lineage that is impaired from undergoing terminal differentiation. NF-κB is constitutively active in cancer cells and plays a critical role in cell survival. Although NF-κB is also activated in RMS, surprisingly, we find that these tumors are far less dependent on NF-κB for their survival. Instead, RMS cells survive, paradoxically, by being partially differentiated under the control of the myogenic transcription factor MyoD. Loss of MyoD, or cellular reprogramming, dedifferentiates RMS tumor cells and sensitizes their death under stress. MyoD enhances RMS survival by regulating DNA methyltransferases, which in turn suppresses the tumor suppressor and pro-apoptotic gene CYLD. From these findings, we propose that MyoD acts as an oncogene in RMS by enhancing survival through pro-differentiation and anti-cell death activities.

Indexed as

CancerCell biology

Identifiers

PMID40799389
PMCPMC12341531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.